CLEARWATER, Fla. - (Business Wire) PanGenex Corporation (Pink Sheets:PGCX) (“PanGenex” or “the Company”) announced today that it anticipates the release of its long form television program, demonstrating the benefits of Calci-CLEAR™, its patent pending dietary supplement that addresses soft tissue calcification, pursuant to its partnership with Incredible Discoveries® in early 2010. Calci-CLEAR™ is a dietary supplement designed to address soft tissue calcification which is the abnormal hardening of soft tissues in the body such as tissues and organs, an important and pervasive condition affecting hundreds of millions of people worldwide.
“This program will allow the Company and its physician partners to reach a broad and diverse audience, an audience where an estimated 1 of every 5 adults has complications associated with soft tissue calcification,” stated Chairman John Stanton.
About Incredible Discoveries®:
Incredible Discoveries®, a wholly-owned subsidiary of O2Media Inc., is a fully integrated production, marketing and investment partnership company that introduces new products to consumers through infomercial development and multi-channel marketing opportunities, including international retail distribution, the highest rated live shopping networks, direct mail catalogs, and insert programs. In addition, Incredible Discoveries® offers a funding option for select product manufacturers that is totally unique to the industry. Incredible Discoveries® hosts a team of dynamic professionals with years of direct response ingenuity and expertise. Their fresh innovative approach has led to successful product launches including the Tornado and the Magic Juice Filter, as well as the international launch of the Didi Car. The organization is a valued member of the Electronic Retailing Association (ERA) and the Direct Response Marketing Alliance (DRMA). For more information about Incredible Discoveries, please visit their website at www.incrediblediscoveries.com.
About PanGenex Corporation:
PanGenex is a publicly traded corporation (Pink Sheets:PGCX) and pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions. Many of our products contain the purest grade of nutraceutical components available anywhere without a prescription. PanGenex markets products through healthcare practitioners, retail establishments and the internet on websites such as www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.
Disclaimer:
Cautionary Statement about Forward-Looking Statements
This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
PanGenex Corporation
Mindy Rippeto, 813-623-5268
investor@pangenex.com
or
Bulova Technologies Group, Inc.
Beverly Mercer, 727-451-6560
